Interventional or Hyperthermia Therapy Combined with FOLFOX Regimen Used in the Postoperative Adjuvant Treatment of Stage Ⅲ Colorectal Cancer Patients
XU Feng,CHEN Shi-wei,LI Yong,FANG Ding-zhu,XU Zhi-feng,SHI Yi,WANG Hai-ping
DOI: https://doi.org/10.3969/j.issn.1007-3969.2011.01.010
2011-01-01
Abstract:Background and purpose:Oxaliplatin(L-OHP) combined with fluorouracil(5-FU) and calcium folinatc(CF) as the standard adjuvant chemotherapy for the patients with stage Ⅲ colorectal cancer.But it leads to many adverse effects.So we look for different methods to get low rates of it.The purpose of this study was to evaluate the effect and toxicity of interventional or hyperthermia therapy combined with FOLFOX regimen used in the postoperative adjuvant treatment of stage Ⅲ colorectal cancer.Methods:We retrospective analyzed 123 patients with stage Ⅲ colorectal cancer,all patients were randomized into 3 groups,57 cases in FOLFOX chemotherapy group(group A),35 cases in chemotherapy plus interventional therapy(group B)and 31 cases in chemotherapy plus hyperthermia therapy(group C).Group A patients were treated with L-OHP plus 5-FU/CF.L-OHP 130 mg/m2 was administered,iv infusion 3.5 h,d 1;CF 200 mg/m2,iv infusion for 2 h,d 1-5;followed by 5-FU 300 mg/m2,iv infusion over a period of 6 h,d 1-5.Group B patients were treated with continuous mesenteric arterial infusion L-OHP plus 5-FU/CF,d 1;the same FL regimen was used in group B.Patients of group C were treated with L-OHP 130 mg/m2 was administered,iv infusion 3.5 h,d 1,received hyperthermia therapy for 1 h at the same time.These treatments were repeated every 3 weeks to a total of 8 cycles.Results:Among 123 patients,the 3 years disease-free survival rates of group A,B and C were 71.9%,77.1% and 77.4% respectively(P=0.793,no statistically significant).The 5 years overall survival rates of group A,B and C were 56.1%,57.1% and 58.1% respectively(P=0.984,no statistically significant).Among the side effects,the neutropenia and peripheral neurologic adverse event of group B and C were less than that of group A and which was significant.Conclusion:Choosing interventional or hyperthermia therapy combined with FOLFOX as an postoperative adjuvant treatment for stage Ⅲ colorectal cancer is safe,effective,and proved to have the similar curative effects as literature reported.